From the Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY (JAL, DHC, NRK, TPS, WWS); Department of Psychology, University of Kentucky College of Arts and Sciences, Lexington, KY (JAL, WWS); Department of Psychiatry, University of Kentucky College of Medicine, Lexington, KY (JAL, WWS); Center for Innovation in Population Health, University of Kentucky College of Public Health, Lexington, KY (BWT); Canopy Growth Corporation, Smiths Falls, Ontario, Canada (MOB-M); and Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (JCS).
J Addict Med. 2023;17(2):e87-e93. doi: 10.1097/ADM.0000000000001059. Epub 2022 Aug 24.
Highly effective treatments for cannabis use disorder (CUD) are lacking, and patient preferences have not been considered during treatment development. We therefore conducted an exploratory crowdsourced survey of individuals reporting current cannabis use and a willingness to cut down or quit their cannabis use, to determine their interest in various treatment aspects.
Subjects (n = 63) were queried about their willingness to take medications as a function of type, route, and regimen and to participate in adherence monitoring. Subjects were also asked about their willingness to engage in behavioral/psychosocial interventions as a function of type, setting, and duration. Measures theorized to be associated with treatment preferences were also collected, including cannabis use variables, readiness to change, reduction or cessation goal, perceived cessation barriers, and medication use beliefs and behaviors.
Survey responses indicated that efforts to develop CUD medications should focus on nonsynthetic compounds administered orally or by mouth spray no more than once per day to maximize patient acceptance. Remote adherence monitoring and one-on-one outpatient behavioral treatment approaches, especially contingency management, are also anticipated to enhance participation. Most subjects indicated a preference to reduce their cannabis use rather than quit.
These data provide guidance for the development of CUD interventions based on the preferences of individuals interested in treatment for their cannabis use. Additional research is needed to confirm these results in a larger sample and determine if matching CUD patients with their preferred treatments improves success rates.
目前缺乏针对大麻使用障碍(CUD)的高效治疗方法,并且在治疗开发过程中并未考虑患者的偏好。因此,我们对报告目前大麻使用情况且愿意减少或戒除大麻使用的个体进行了一项探索性的众包调查,以确定他们对各种治疗方面的兴趣。
根据类型、途径和方案询问了受试者(n=63)对服用药物的意愿,以及对参与药物依从性监测的意愿。还询问了他们对参与行为/心理社会干预的意愿,包括类型、地点和持续时间。还收集了与治疗偏好相关的理论上的措施,包括大麻使用变量、改变意愿、减少或停止目标、感知停止障碍以及药物使用信念和行为。
调查结果表明,开发 CUD 药物的努力应侧重于每天口服或经口喷雾施用的非合成化合物,以最大限度地提高患者的接受度。远程依从性监测和一对一的门诊行为治疗方法,特别是行为矫正,也有望提高参与度。大多数受试者表示更倾向于减少而不是戒除大麻。
这些数据为基于对治疗其大麻使用有兴趣的个体的偏好来开发 CUD 干预措施提供了指导。需要进一步的研究来在更大的样本中确认这些结果,并确定是否将 CUD 患者与他们首选的治疗方法相匹配可以提高成功率。